How Irrationality Has Sparked the Dow Jones Industrial Average (.DJI)’s Triple-Digit Plunge

Page 2 of 2

The firm’s melanoma drug lambrolizumab posted strong clinical data at the American Society of Clinical Oncology this past weekend, reducing the growth of tumors in late-stage melanoma patients by 38%. Merck & Co., Inc. (NYSE:MRK) has struggled with falling sales as a result of patent expirations — particularly on its top-selling therapy, Singulair — and if lambrolizumab can pass regulatory hurdles and live up to its blockbuster expectations, the drug will go a long way toward firming up Merck & Co., Inc. (NYSE:MRK)’s future.

The article How Irrationality Has Sparked the Dow’s Triple-Digit Plunge originally appeared on Fool.com is written by Dan Carroll.

Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Amazon.com and Home Depot. The Motley Fool owns shares of Amazon.com and International Business Machines (NYSE:IBM).

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Page 2 of 2